Cargando…
Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
BACKGROUND: The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact recommendations. The objective of this project was to adapt a set of prioritized...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682746/ https://www.ncbi.nlm.nih.gov/pubmed/36414983 http://dx.doi.org/10.1186/s41927-022-00301-y |
_version_ | 1784834920795865088 |
---|---|
author | Omair, Mohammed A. Al Rayes, Hanan Khabsa, Joanne Yaacoub, Sally Abdulaziz, Sultana Al Janobi, Ghada A. Al Khalaf, Abdulaziz Al Mehmadi, Bader Al Nassar, Mahasin AlBalawi, Faisal AlFurayj, Abdullah S. Al-Jedai, Ahmed Hamdan Almalag, Haya Mohammed Almudaiheem, Hajer Yousef AlRehaily, Ali Attar, Mohammed A. El Kibbi, Lina Halabi, Hussein Hasan, Manal Singh, Jasvinder A. Fraenkel, Liana Akl, Elie A. |
author_facet | Omair, Mohammed A. Al Rayes, Hanan Khabsa, Joanne Yaacoub, Sally Abdulaziz, Sultana Al Janobi, Ghada A. Al Khalaf, Abdulaziz Al Mehmadi, Bader Al Nassar, Mahasin AlBalawi, Faisal AlFurayj, Abdullah S. Al-Jedai, Ahmed Hamdan Almalag, Haya Mohammed Almudaiheem, Hajer Yousef AlRehaily, Ali Attar, Mohammed A. El Kibbi, Lina Halabi, Hussein Hasan, Manal Singh, Jasvinder A. Fraenkel, Liana Akl, Elie A. |
author_sort | Omair, Mohammed A. |
collection | PubMed |
description | BACKGROUND: The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact recommendations. The objective of this project was to adapt a set of prioritized recommendations from the 2021 ACR guideline for the treatment of rheumatoid arthritis RA for the context of Saudi Arabia, by the Saudi Society for Rheumatology (SSR). METHODS: The process followed the GRADE-ADOLOPMENT methodology, and the reporting adhered to the RIGHT-Ad@pt checklist. Working groups included a coordination group and a 19-member panel representing different stakeholder groups. The Evidence to Decision (EtD) tables included evidence on health effects from the source guideline and contextual information from the Saudi setting. RESULTS: The panel prioritized and adapted five recommendations from the source guideline. The process led to modifying two out of the five prioritized recommendations, all listed here. In naive patients with low disease activity, methotrexate (MTX) is conditionally recommended over sulfasalazine (SSZ) (modified direction); hydroxychloroquine (HCQ) is conditionally recommended over SSZ (unmodified). Initiation of csDMARDs with short-term glucocorticoids is conditionally recommended over csDMARDs alone in naive patients with moderate to high disease activity (modified direction). Switch to subcutaneous MTX is conditionally recommended over addition/switch to alternative DMARD(s) in patients taking oral MTX who are not at target (unmodified). Discontinuation of MTX is conditionally recommended over gradual discontinuation of the bDMARD or tsDMARD for patients taking MTX plus a bDMARD or tsDMARD who wish to discontinue a DMARD (unmodified). CONCLUSION: Rheumatologists practicing in Saudi Arabia can use the adoloped recommendations generated by this project while adopting the rest of the recommendations from the 2021 ACR guidelines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-022-00301-y. |
format | Online Article Text |
id | pubmed-9682746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96827462022-11-24 Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines Omair, Mohammed A. Al Rayes, Hanan Khabsa, Joanne Yaacoub, Sally Abdulaziz, Sultana Al Janobi, Ghada A. Al Khalaf, Abdulaziz Al Mehmadi, Bader Al Nassar, Mahasin AlBalawi, Faisal AlFurayj, Abdullah S. Al-Jedai, Ahmed Hamdan Almalag, Haya Mohammed Almudaiheem, Hajer Yousef AlRehaily, Ali Attar, Mohammed A. El Kibbi, Lina Halabi, Hussein Hasan, Manal Singh, Jasvinder A. Fraenkel, Liana Akl, Elie A. BMC Rheumatol Research BACKGROUND: The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact recommendations. The objective of this project was to adapt a set of prioritized recommendations from the 2021 ACR guideline for the treatment of rheumatoid arthritis RA for the context of Saudi Arabia, by the Saudi Society for Rheumatology (SSR). METHODS: The process followed the GRADE-ADOLOPMENT methodology, and the reporting adhered to the RIGHT-Ad@pt checklist. Working groups included a coordination group and a 19-member panel representing different stakeholder groups. The Evidence to Decision (EtD) tables included evidence on health effects from the source guideline and contextual information from the Saudi setting. RESULTS: The panel prioritized and adapted five recommendations from the source guideline. The process led to modifying two out of the five prioritized recommendations, all listed here. In naive patients with low disease activity, methotrexate (MTX) is conditionally recommended over sulfasalazine (SSZ) (modified direction); hydroxychloroquine (HCQ) is conditionally recommended over SSZ (unmodified). Initiation of csDMARDs with short-term glucocorticoids is conditionally recommended over csDMARDs alone in naive patients with moderate to high disease activity (modified direction). Switch to subcutaneous MTX is conditionally recommended over addition/switch to alternative DMARD(s) in patients taking oral MTX who are not at target (unmodified). Discontinuation of MTX is conditionally recommended over gradual discontinuation of the bDMARD or tsDMARD for patients taking MTX plus a bDMARD or tsDMARD who wish to discontinue a DMARD (unmodified). CONCLUSION: Rheumatologists practicing in Saudi Arabia can use the adoloped recommendations generated by this project while adopting the rest of the recommendations from the 2021 ACR guidelines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-022-00301-y. BioMed Central 2022-11-23 /pmc/articles/PMC9682746/ /pubmed/36414983 http://dx.doi.org/10.1186/s41927-022-00301-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Omair, Mohammed A. Al Rayes, Hanan Khabsa, Joanne Yaacoub, Sally Abdulaziz, Sultana Al Janobi, Ghada A. Al Khalaf, Abdulaziz Al Mehmadi, Bader Al Nassar, Mahasin AlBalawi, Faisal AlFurayj, Abdullah S. Al-Jedai, Ahmed Hamdan Almalag, Haya Mohammed Almudaiheem, Hajer Yousef AlRehaily, Ali Attar, Mohammed A. El Kibbi, Lina Halabi, Hussein Hasan, Manal Singh, Jasvinder A. Fraenkel, Liana Akl, Elie A. Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines |
title | Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines |
title_full | Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines |
title_fullStr | Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines |
title_full_unstemmed | Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines |
title_short | Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines |
title_sort | recommendations for the treatment of rheumatoid arthritis in saudi arabia: adolopment of the 2021 american college of rheumatology guidelines |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682746/ https://www.ncbi.nlm.nih.gov/pubmed/36414983 http://dx.doi.org/10.1186/s41927-022-00301-y |
work_keys_str_mv | AT omairmohammeda recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT alrayeshanan recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT khabsajoanne recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT yaacoubsally recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT abdulazizsultana recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT aljanobighadaa recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT alkhalafabdulaziz recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT almehmadibader recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT alnassarmahasin recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT albalawifaisal recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT alfurayjabdullahs recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT aljedaiahmedhamdan recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT almalaghayamohammed recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT almudaiheemhajeryousef recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT alrehailyali recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT attarmohammeda recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT elkibbilina recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT halabihussein recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT hasanmanal recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT singhjasvindera recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT fraenkelliana recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines AT akleliea recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines |